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ABSTRACT
Purpose The clinical application of holmium acetylacetonate
microspheres (HoAcAcMS) for the intratumoral radionuclide
treatment of solid malignancies requires a thorough under-
standing of their stability. Therefore, an in vitro and an in vivo
stability study with HoAcAcMS was conducted.
Methods HoAcAcMS, before and after neutron irradiation,
were incubated in a phosphate buffer at 37°C for 6 months.
The in vitro release of holmium in this buffer after 6 months
was 0.5%. Elemental analysis, scanning electron microscopy,
infrared spectroscopy and time of flight secondary ion mass
spectrometry were performed on the HoAcAcMS.
Results After 4 days in buffer the acetylacetonate ligands were
replaced by phosphate, without altering the particle size and
surface morphology. HoAcAcMS before and after neutron
irradiation were administered intratumorally in VX2 tumor-
bearing rabbits. No holmium was detected in the faeces, urine,
femur and blood. Histological examination of the tumor
revealed clusters of intact microspheres amidst necrotic tissue
after 30 days.
Conclusion HoAcAcMS are stable both in vitro and in vivo and
are suitable for intratumoral radionuclide treatment.
KEY WORDS brachytherapy.holmium.in vivo.
microspheres.VX2carcinoma
INTRODUCTION
Worldwide, cancer is the second cause of death, after
cardiovascular diseases (1), and it is estimated that each
year over 20 million new cases are presented (2). The
majority (over 90%) of these new cases are solid tumors,
and each year over 12 million people die from solid tumors
(1,2). Traditionally, surgery has been the preferred treat-
ment of solid malignancies, since this treatment can be
considered curative (3), but, unfortunately, not all tumors
are eligible for curative resection. In the 1990s minimally
invasive treatment options were proposed as treatment of
inoperable solid malignancies, to offer a potentially curative
treatment and to reduce the morbidity associated with
surgery. These minimally invasive treatments, which are
increasingly applied nowadays, include radiofrequency
ablation (4), high intensity focused ultrasound (5) and local
administration of radionuclides (6,7). With respect to the
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embolization of liver malignancies using radioactive micro-
spheres (8,9). This technique involves the administration of
yttrium-90 (
90Y) microspheres using a catheter placed in the
hepatic artery. Another approach is the direct intratumoral
injection of radiolabeled particles or substances. Intra-
tumorally administered
90Y glass microspheres have been
successfully tested in humans (6). The results were
promising: 90.6% of the tumors treated showed a size
reduction, and apparent complete tumor necrosis was
observed in 8 patients. Although these results were very
promising, the extrahepatic delivery of microspheres,
especially to the lungs, and the lack of accurate dose
estimations were posed as problems to be overcome. Also,
intratumoral administration of holmium-166 (
166Ho)
chelated to chitosan, an in situ gel forming device, has
been tested in hepatocellular carcinoma patients with
small (≤3 cm) solitary lesions (10). Complete tumor
necrosis was observed in 31 of 40 patients, yet the release
of holmium from the injection site led to haematologic
side effects in 11 of 40 patients. In itself,
166Ho is an ideal
isotope since, in contrast to
90Y, it combines the emission
of therapeutic beta particles with gamma rays. The
gamma rays can be accurately visualized using gamma
scintigraphy, which can be used for accurate dosimetric
calculations. Moreover, holmium is a paramagnetic and
electron dense element, allowing for magnetic resonance
imaging and x-ray computed tomography (CT), respec-
tively (11). Chitosan as a delivery device for
166Ho
however is not ideal due to leakage of
166Ho from the
complex, causing haematologic side effects. To further
optimize the intratumoral application of
166Ho, holmium
microspheres with an ultra high holmium load were
proposed as a radioablation device for solid malignancies
(12). These microspheres were suitable to deliver sufficient
radiation after intratumoral administration, and their
efficacy was tested in a renal cell carcinoma tumor-
bearing mouse model (13). The microsphere treated
tumors did not show a significant growth (141±99 mm
3 at
time of treatment versus 104±95 mm
3 after 2 weeks), whereas
the tumor size in the saline treated control group increased
dramatically (from 122±33 mm
3 to 4,150±300 mm
3
2 weeks post-injection). In addition to the laboratory animal
study, a pilot experiment was performed to assess the
feasibility and tolerability of intratumoral administration of
166HoAcAcMS in feline liver cancer patients (14). The
treatment was well tolerated, and the clinical condition of
the cats improved. It was concluded that intratumoral
administration of
166HoAcAcMS is efficacious, and not
associated with adverse effects.
The purpose of the present study was to investigate the
long-term in vitro stability of these radioactive holmium
acetylacetonatemicrospheres(
166HoAcAcMS). The holmium
release from the HoAcAcMS was measured and the
surface morphology and the chemical composition of the
HoAcAcMS were investigated upon incubation of both
non-neutron activated and neutron activated radioactive
HoAcAcMS in phosphate buffer at 37°C for up to
26 weeks. The in vivo stability was assessed in VX-2
tumor-bearing rabbits, after intratumoral administration
of both non-activated HoAcAcMS and neutron-activated
HoAcAcMS. The rabbits were followed for 1 month,
during which blood, urine and faeces were collected to
determine the excretion of holmium. Histology was
performed on tumor tissue, and the holmium content in
the femur was determined.
MATERIALS AND METHODS
Materials
All chemicals were commercially available and used as
received. Acetylacetone (2,4-pentanedione (AcAc; >99%)),
ammonium hydroxide (NH4OH; 29.3% in water), chloroform
(CHCl3; HPLC-grade), holmium phosphate (anhydrous
(HoPO4; >99.99+%), poly(vinyl alcohol) (PVA; average
MW 30,000–70,000, 88% hydrolyzed) and poloxamer 188
(Pluronic
® F68, average MW 8350) were purchased from
Sigma Aldrich (Steinheim, Germany). Di-sodium hydrogen
phosphate dihydrate (Na2HPO4.2H2O; 99%), ethanol
(absolute), holmium CertiPUR ICP Standard (1.00 g L
−1),
sodium azide (NaN3; 99%) and sodium dihydrogen
phosphate dihydrate (NaH2PO4
.2H2O; 99%) were purchased
from Merck (Darmstadt, Germany). Holmium chloride
hexahydrate (HoCl3.6H2O) was obtained from Metall rare
earth (Shenzhen, China). Dexmedetomedine (Dexdomitor)
and carprofen (Rimadyl) were obtained from Pfizer Animal
Health B.V. (Capelle a/d IJssel, The Netherlands) and
Isoflurane (IsoFlo) was obtained from Abbott Animal Health
(Hoofddorp, The Netherlands).
Preparation and Neutron Irradiation of HoAcAcMS
HoAcAcMS with a size of 15 μm were prepared by a
solvent evaporation process previously described (12).
The HoAcAcMS (300 or 600 mg) were weighed in high
density polyethylene vials (Type A, Posthumus plastics,
Beverwijk, the Netherlands). Neutron irradiations were
performed in the pneumatic rabbit system operational
at the research reactor facility of the Reactor Institute
Delft (Delft University of Technology, The Netherlands)
(15) .S a m p l e sw e r ei r r a d i a t e df o re i t h e r3ho r6hw i t ha
thermal neutron flux of 5×10
12 nc m
−2 s
−1,a n dt h e
radioactive
166Ho was left to decay for 1 month in closed
vials.
828 Bult et al.In Vitro Degradation of the Microspheres
The release of Ho
3+-ions from HoAcAcMS was determined
as described by Zielhuis et al.( 16). Neutron irradiated
microsphere samples (50 mg) were suspended in 100 μlo f
2% Pluronic
® F68 aqueous solution and incubated in test
tubes containing 5 mL isotonic phosphate buffer
(116 mM, 39 mmol of NaH2PO4·2H2O and 77 mmol
of Na2HPO4·2H2O in 1 L, pH 7.4) with 0.05% NaN3 to
prevent bacterial growth. All samples were prepared in
duplicate. The tubes were placed in a water bath at 37°C
and continuously shaken and at predetermined time points
(1 day, 4 days, 1, 2, 4, 8, 12 and 24 weeks) the test tubes
were centrifuged, and the supernatant was collected. The
microspheres were washed three times with water for
injection and dried at 50°C. The microspheres and the
supernatant were used for further analysis.
Particle Surface Morphology
Surface morphology of the HoAcAcMS after incubation
was studied using a Phenom (Phenom World BV, Eindhoven,
The Netherlands) scanning electron microscope. The
samples were placed on aluminium stubs and sputter
coated with a 6 nm Pt layer, and images were acquired
at a voltage of 5 kV.
Elemental Analysis
The holmium, carbon, oxygen, hydrogen and phosphorous
content was determined before and after incubation of
HoAcAcMS in phosphate buffer by H. Kolbe (Mulheim an
der Ruhr, Germany).
Infrared Spectroscopy
Fourier Transform Infrared spectroscopy was used to
ascertain the presence of acetylacetonate in the microspheres.
Infrared spectra of dried microspheres were acquired on
a BIO-RAD FTS6000 FT-IR (BIO-RAD, Cambridge,
MA, USA). The spectra were recorded from 400 to
4,000 cm
−1 using KBr pellets, by accumulating 256 scans
per spectrum.
Secondary Ion Mass Spectrometry
Time of flight secondary ion mass spectrometry (TOF-
SIMS) analysis was performed to obtain mass spectral
information about the molecular composition and
distribution on the surface of the microspheres before
and after incubation in buffer (17). Samples were fixed
on a conductive carbon sticker on a stainless steel sample
holder, and measured using a TRIFT II mass spectrometer
(Physical Electronics, Eden Prairie, MN) equipped with a Au
primary ion gun. 22 keV Au
+ primary ions were used for
analysis. SIMS spectra were measured both in the positive
and the negative secondary ion mode with a secondary ion
energy of 7 keV.
In Vivo Degradation Study
Animal Model
All experimental protocols and procedures were approved
by the local experimental animal welfare committee and
conform to national and European regulations for animal
experimentation. Eight adult female New Zealand White
rabbits of approximately 3.5 kg were purchased from
Harlan (Horst, The Netherlands). The animals were housed
individually to allow for urine and faeces collection and
were fed approximately 100 g complete diet pellets for
rabbits daily. Water was supplied ad libitum.
Tumor Cells
The VX2 cell line was a kind gift from dr. R.J.J. van Es
(department of Oral and Maxillofacial surgery, University
Medical Centre Utrecht, Utrecht, The Netherlands) (18).
The VX2 cells were propagated by subcutaneous passage in
the rabbit hind limb. After dissecting the tumor, small
portions of viable tumor (2 mm in diameter) were selected
for intrahepaticimplantationas describedby Nijsenet al.( 19).
Analgesia, Sedation and Euthanasia
Analgesia during and 2 days post laparotomy was achieved
with carprofen s.c. 4 mg kg
−1 bodyweight. General
anaesthesia was induced by ketamine i.m. at 30 mg kg
−1
bodyweight and xylazine i.m. at 4 mg kg
−1 bodyweight.
Anaesthesia was maintained by inhalation of isoflurane
Fig. 1 ReleaseofholmiumfromHoAcAcMS(diamonds)a n d
166HoAcAcMS
irradiated for either 3 h (triangles)o r6h( squares) during incubation in
phosphate buffer for 6 months. The data are presented as the mean of two
measurements.
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the animals were sedated using dexmedetomidine at
50 mg kg
−1 and ketamine at 15 mg kg
−1. The animals
were euthanized by intravenous injection of 600 mg
pentobarbital.
Tumor Implantation
A subxiphoid laparotomy was performed by ventral mid-
line incision, in order to expose the liver lobes. Three tumor
pieces were implanted into the left lateral liver lobe with an
intravenous catheter (Abbocath−T 16 G, Hospira, Donegal
Town, Ireland). After implantation of tumor tissue, the
puncture wound in the liver was sealed with tissue glue
(Histoacryl, B. Braun, Melsungen, Germany). Thereafter
the abdominal muscle layer and skin layers were sutured in
separate layers using Vicryl 3.0 (Johnson&Johnson Intl., St-
Stevens-Woluwe, Belgium).
Dose Preparation
Neutron irradiation of approximately 60 mg HoAcAcMS
for 1 h resulted in an activity of approximately 600 MBq
166HoAcAcMS. The
166HoAcAcMS were suspended in
1.2 mL of sterile water containing 2% Pluronic
® F68 and
10% ethanol abs. to obtain a final concentration of
Fig. 2 Scanning electron micrographs of HoAcAcMS and
166HoAcAcMS after incubation for different times in phosphate buffer. (a–c) HoAcAcMS, (a)
after 1 month, (b) after 3 months and (c) after 6 months of incubation. (d–f)
166HoAcAcMS neutron irradiated for 3 h at a neutron flux of 5×10
12 n
cm
−2 s
−1 (d)a f t e r1m o n t h ,( e)a f t e r3m o n t h sa n d( f) after 6 months of incubation. (g–i)
166HoAcAcMS neutron irradiated for 6 h at a neutron flux of 5×
10
12 nc m
−2 s
−1 (g)a f t e r1m o n t h ,( h) after 3 months and (i) after 6 months of incubation. The magnification in all images is 1000x, the bar represents 50 μm.
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−1 (=500 MBq
166HoAcAcMS mL
−1). The
microspheres were suspended by gentle agitation and
repeatedly drawing them up and down with a syringe.
Subsequently, approximately 200 μL (=100 MBq or 10 mg
166HoAcAcMS) was taken up in 29 G insulin syringes
(Becton Dickinson Ultra Fine, Breda, the Netherlands),
and the activity was measured using a dose calibrator
(VDC-404, Veenstra Instruments, Joure, The Netherlands).
As a control, a suspension of non-radioactive microspheres
was prepared in a similar concentration of microspheres
(50 mg mL
−1). Approximately 200 μL (or 10 mg) was taken
up in 29 G insulin syringes.
Administration of
166HoAcAcMS
Fourteen days post implantation the tumor reached a
size of approximately 2 cm
3 and a second subxiphoid
laparotomy was performed. Prior to administration of the
microspheres, the syringe was agitated vigorously to obtain
a homogeneous microsphere suspension. One hundred μl
of non-radioactive (=5 mg) or radioactive HoAcAcMS
(=50 MBq, which corresponds to 5 mg) suspension was
administered intratumorally. The syringes were measured
in a dose calibrator before and after administration, to
determine the injected amount of activity. Following the
intratumoral administration of
166HoAcAcMS, the animals
were subjected to planar gamma scintigraphy (Forte,
Philips Medical Systems, Best, The Netherlands) and CT
imaging (Brilliance 64, Philips Medical Systems, Best,
The Netherlands) to confirm the selective deposition of
microspheres in the tumor.
Release Profile of the
166HoAcAcMS
The urine and faeces of the animals were collected at
t h es a m et i m ee a c hd a yd u r i n gt h ef i r s tw e e ka f t e r
Table I Elemental Composition of the HoAcAcMS after Incubation in a 116 mM Phosphate Buffer
Day 0
a Day 1 Day 4 Day 7 Day 30 Day 90
%
b no
c % no % no % no % no % no
C 26.4 7.5 15.0 4.4 1.0 0.3 0.6 0.2 0.5 0.1 0.7 0.2
H 4.0 13.5 3.5 12.0 1.5 4.9 2.2 7.5 1.5 4.5 1.6 4.6
O 20.3 4.3 29.0 6.3 35.4 7.2 37.9 8.1 30.9 5.7 30.1 5.6
Ho 48.4 1.0 47.2 1.0 50.8 1.0 48.2 1.0 55.5 1.0 55.8 1.0
P 0.5 0.05 5.2 0.6 10.7 1.1 10.7 1.2 11.3 1.1 11.0 1.0
Composition
d Ho2(AcAc)3 *H 2O Intermediate HoPO4 *3H 2O HoPO4 *3H 2O HoPO4 *3H 2O HoPO4 *3H 2O
adata taken from Bult et al.( 12)
bresults from elemental analysis are the mean of two values
cno: the number of atoms, normalized on holmium
dComposition: the chemical composition of the particles
Fig. 3 TOF-SIMS spectra from control HoAcAcMS (HoAcAcMS) and buffer incubated HoAcAcMS (HoAcAcMS buffer). The micrographs show total ion
count images in the negative (−ve) and the positive (+ve) secondary ion mode. The peaks of interest are indicated with an arrow.
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taken before, just after, 5 days after and 10 days after
administration of HoAcAcMS. Blood was centrifuged at
3,000 rpm for 10 min at 4°C and the serum was
collected and stored at −20°C for further analysis. The
serum levels of alkaline phosphatase (ALP) as an
indicator of biliary toxicity, alanine aminotransferase
(ALAT), aspartate amino transferase (ASAT) and gamma
glutamyltransferase (γ-GT) as indicators of hepatocellular
toxicity and albumin as indicat o rf o rl i v e rf u n c t i o nw e r e
analysed on a UniCel DxC 800 Clinical System (Beckman
Coulter B.V., Woerden, The Netherlands). In addition,
the serum holmium levels were measured using inductively
coupled plasma−optical emission spectroscopy (ICP OES),
as described in section 2.9.
Histology
Rabbits were euthanized 4 weeks after administration
of HoAcAcMS. After termination, the lungs, heart,
stomach, liver, kidneys, and a femur were excised and
f i x e di na4 %f o r m a l i ns o l u t i o n .T h et u m o rb e a r i n g
liver was dissected and embedded in paraffin. After
haematoxylin-eosin staining the liver and tumor tissue
was histologically evaluated, to verify the presence of
microspheres in the tumor and liver.
Determination of Holmium Concentration
Theholmiumconcentrationinbuffer,serum,urine,faecesand
bone samples was determined using ICP OES. Buffer samples
werepreparedbydiluting100μLofsupernatantto5mLnitric
acid (5% w/v). Approximately 1 g of urine or faeces sample
was destructed overnight using 5 mL nitric acid (30%). After
overnight destruction the samples were centrifuged at 4,000 g
and 1 mL of supernatant was diluted to 5 ml with nitric acid
(5% w/v). The bone was separated from the marrow of the
femur samples. Approximately 500 mg bone sample was
weighed accurately, and was destructed in 4 mL aqua regia
(one volume of nitric acid (65% w/w) mixed with three
volumes hydrochloric acid (36% w/w)) under heating to
100°C.Afterevaporationtodryness,theresiduewasdissolved
in 5 mL nitric acid (5% w/v). All samples were measured at
three different wavelengths (339.898 nm, 345.600 nm and
347.426 nm respectively) by ICP-OES, using an Optima
4300 (PerkinElmer, Norwalk, USA). Analytical calibration
curves from the holmium ICP standard solution were used
to assess the precision and accuracy of the measurements.
Fig. 4 (a) Schematic outline of rabbit anatomy on X-ray CT image (L=liver, T=tumor, S=stomach, I=intestine). (b) X-ray CT image of rabbit before
intratumoral administration of
166HoAcAcMS showing the tumor, (c) X-ray CT image of rabbit after intratumoral administration of
166HoAcAcMS showing
the selective deposition in the tumor as white artifacts, (d) X-ray CT image 4 weeks after administration, before termination, the white area in the tumor is
still present as a cluster, although the shape has changed.
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Microsphere characteristics of the HoAcAcMS used in
these experiments were in accordance with previous
work (12). The microspheres had a holmium load of 45±
1%, and a size of 15 μm (97% of the microspheres
between 10 and 20 μm) after sieving. As previously
observed, no differences in size distribution were observed
before and after neutron irradiation, irrespective of
irradiation time (12).
The in vitro release profile of holmium from the
microspheres incubated in phosphate buffer is shown in
Fig. 1. As can be observed, the release of holmium was
below 0.5% after 6 months. This is comparable to the
holmium release (0.7±0.2%) reported for holmium loaded
poly(L-lactic acid) microspheres (HoPLLAMS) in the same
buffer (16). The HoPLLAMS are considered radiochemically
stable and are currently under clinical investigation in a Phase
I study for treatment of liver malignancies (20).
Electron microscopic inspection of the HoAcAcMS
after incubation in phosphate buffer showed clusters of
microspheres amidst buffer. Since the surface charge of
the HoAcAcMS is expected to be near neutral (21), the
microspheres aggregate upon settling due to gravitational
forces. The phosphate buffer filled the inter-microsphere
spaces which turned into buffer salts upon drying, thereby
encapsulating the microspheres. The microspheres
remained intact, irrespective of the neutron irradiation
time and incubation time (Fig. 2). The surface of the
microspheres was still smooth after 26 weeks in buffer.
This finding is in contradistinction to neutron irradiated
HoPLLAMS incubated in a similar buffer (16)w h i c h
showed a rough surface after 12 weeks of incubation and
started to disintegrate after 24 weeks incubation. This
disintegration was attributed to hydrolysis of the poly(L-lactic
acid), leading to the formation of holmium lactate (16).
The HoAcAcMS were subjected to elemental analysis to
determine their composition after incubation in phosphate
buffer (Table I). Interestingly, a quantitative exchange of
acetylacetonate by phosphate was observed within 4 days of
incubation. To confirm the exchange of acetylacetonate by
phosphate, IR analysis was performed. The characteristic
Fig. 5 Serum enzyme levels (ASAT, ALAT, γ-GT, ALP and albumin) of rabbits that received non-radioactive HoAcAcMS (solid line) and radioactive
166HoAcAcMS (dotted line) in time. Bars represent SD.
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−1 are
present in the samples before and after 1 day of incubation
in buffer. The intensity of this peak reduces in time and
after 1 month it could not be observed anymore.
Interestingly, after 4 days a broad peak around
1,100 cm
−1 appeared, which can be attributed to stretching
bands of phosphate groups (22).
TOF-SIMS analysis of HoAcAcMS before and after
incubation in buffer showed spherical particles in total ion
count mode (Fig. 3). The resulting mass spectrum showed
differences between HoAcAcMS incubated in phosphate
buffer and HoAcAcMS before incubation in buffer. The
negative ions observed in the HoAcAcMS incubated in
buffer were oxygen, chlorine, and phosphorous compounds
(m/z 31: P
-; m/z 63: PO2
-; m/z 79 PO3
-), which were absent
in the spectrum of the non incubated microspheres
(Fig. 3). All negative ions were distributed evenly through
the microspheres, indicating a complete exchange of
acetylacetonate by phosphate in the microspheres. Holmium
(m/z 165), and holmium-oxygen (m/z 181) was present in
both the incubated and non incubated samples. The
incubated samples also showed a large peak of sodium
(m/z 23) from the buffer salts, which was only present at
the particle surface. The HoAcAcMS before incubation in
phosphate buffer show additional peaks in the positive
secondary ion mode at m/z 74 and m/z 147, which can be
attributed to trimethylsilylgroups from polydimethylsiloxane
(23) that is present on the surface of the carbon sticker.
The results of IR analysis and TOF-SIMS confirm
elemental analysis data that phosphate has replaced acetyla-
cetonate after suspension in buffer. This in turn explains the
limited release of holmium from the microspheres, since rare
earth metal phosphates are practically insoluble in aqueous
media; the solubility product of HoPO4 in water is lower than
10
−25 M( 24). The exchange of acetylacetonate by phosphate,
without changing the surface morphology, is a so called chimie
douce reaction (25). Chimie douce reactions are topotactic
meaning that the products retain the precursor geometry,
and usually take place under mild conditions. Beta diketones,
like acetylacetonate, are prone to these types of reactions
(26,27).
The in vivo stability study was carried out to determine
the in vivo implications of the results obtained in the in vitro
experiment. Radioactive and cold HoAcAcMS were
administered intratumorally to VX2 carcinoma-bearing
rabbits. All animals recovered from anaesthesia, and the
animalsreceived40±10MBq
166HoAcAcMS, corresponding
to 4±1 mg microspheres intratumorally. Approximately
80% of the intended dose was administered, which was
attributed to the premature settling of the microspheres in
the syringes. Nuclear imaging and CT imaging showed a
selective administration of microspheres in the tumor
(Fig. 4). One animal showed uptake of activity in the
lungs (approximately 5% of the injected dose) apart from
uptake in the tumor, due to the inadvertent delivery of
166HoAcAcMS in a blood vessel surrounding the tumor
artery. This animal however, completed the experiment in
good health. The inadvertent delivery of activity can be
avoided in humans by administering the microspheres
under ultrasound guidance, making it easier to distinguish
tumor tissue from blood vessels and liver tissue (6).
The excretion of holmium after intratumoral adminis-
tration of HoAcAcMS to the blood, urine and the faeces
was below the detection limit in all samples (0.1 ppm for
Ho). Suzuki and co-workers found that release of free
holmium (Ho
3+) to the urine and faeces occurred rapidly
after local intrahepatic administration of the in-situ gel
forming complex holmium-166-chitosan (28). Therefore it
can be concluded that Ho
3+ was not released from the
HoAcAcMS, and that the microspheres retained their
integrity as confirmed by histology.
Fig. 6 Light micrographs at 400x magnification of a H&E stained
section of tumor tissue showing microspheres amidst necrotic tissue.
(a) non-radioactive HoAcAcMS. (b)
166HoAcAcMS. The microspheres in
red are clustered amidst necrotic tissue. The bar represents 20 μm.
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stability study show a minimal to no release of holmium
from the HoAcAcMS, the in vivo data cannot be related to
the chimie douce reaction found in vitro. The phosphate
concentration (116 mM) used for the in vitro experiment is
substantially higher than the phosphate concentration in
human serum (around 1.5 mM (29)). The high phosphate
concentration in vitro was required to keep the pH stable
throughout the experiment, which, however, might
accelerate the exchange of acetylacetonate by phosphate.
The exchange of acetylacetonate by phosphate could not
be established in vivo s i n c ep a r a f f i ni n t e r f e r e dw i t ht h e
TOF-SIMS measurements, nonetheless, the presence of
intact microspheres and the absence of holmium in urine,
faeces and blood show that the HoAcAcMS are stable in
vivo. The identification of the chemical structure of the
HoAcAcMS after intratumoral administration requires
further research.
A transient rise in ASAT was observed after the
administration of the radioactive microspheres, which can
be attributed to the subxiphoid manipulation of liver
tissue, and radiation effects of the
166HoAcAcMS. No
other elevations from baseline levels or differences in
serum enzyme levels were found between the radioactive
and non-radioactive group (see Fig. 5). ASAT and ALAT
are markers for short term liver damage, whereas gamma
GT and Alkaline Phosphatase are a measure for long-term
(chronic) liver damage. Albumin levels are a marker for
the liver function, since the liver is the main site for
albumin production (30). The transient rise in ASAT was
previously observed after transcatheter radioembolization
with both
90Y microspheres in human liver cancer patients
(31)a n d
166HoPLLAMS in healthy pigs (30). This transient
rise was attributed to the manipulation of liver tissue and
radiation effects of the microspheres (30,31). No changes
in serum enzyme levels or albumin levels were observed
in the present study, an indication that the liver function
was neither impaired by the tumor, nor intratumoral
administration of either HoAcAcMS or
166HoAcAcMS.
Histological evaluation of liver sections showed intact
microspheres amidst necrotic tissue both for HoAcAcMS
and
166HoAcAcMS (Fig. 6), which is in agreement with the
results from the in vitro stability study showing intact
HoAcAcMS after 6 months incubation in buffer (Fig. 2).
Boththenon-radioactiveHoAcAcMSandthe
166HoAcAcMS
are surrounded by necrotic tissue. The VX2 tumor is a
rapid-growing tumor, with a viable rim and a necrotic core.
Therefore, the HoAcAcMS are surrounded by necrotic
tissue (Fig. 6a). Radiation damage from the
166HoAcAcMS
resulted in the necrotic tissue surrounding the cluster of
microspheres (Fig. 6b).
Possible release of holmium from the HoAcAcMS was
determined by measuring the holmium content in bone.
Holmium is a bone seeking element, and it has been shown
that within 4 days after intravenous administration of
holmium nitrate, approximately 55% of the injected dose
accumulates in bone (32). Therefore, if holmium (Ho
3+)
would be released from the HoAcAcMS in vivo,t h e
holmium levels in bone would be elevated. In accordance
with the holmium levels in urine and faeces, the holmium
levels in all bone samples were below the detection limit
and it can be concluded that no release of holmium from
the HoAcAcMS has occurred.
CONCLUSION
This paper demonstrates the stability of HoAcAcMS,
both in vitro and in vivo.T h ein vitro release was
approximately 0.5% after 6 months of incubation in
buffer. The microspheres remained spherical, and a
HoPO4 complex was formed while the surface morphology
was retained. No release of holmium was observed after
the intratumoral injection of HoAcAcMS in VX2
tumor-bearing rabbits, and the microspheres remained
intact in tumor tissue for 1 month. The results confirm
the potential of these microspheres as a novel intratumoral
radioablation device.
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